Hair Loss On GLP-1

Alopecia is listed as an adverse reaction in the FDA-approved prescribing information for Zepbound. It was added to Mounjaro's label in February 2025 as a post-marketing finding. In the Wegovy studies, hair loss was reported in 3% of adults compared with 1% on placebo. Most people prescribed these medications were never told any of that, because the conversation at a telehealth platform does not usually get that far. The picture got sharper this summer. A study published in the BMJ in July 2026 found that adults taking GLP-1 receptor agonists had a meaningfully higher rate of clinically recorded hair loss than people on other diabetes medications, and the FDA has said it is now evaluating this as a safety signal. The absolute risk remains low, and the shedding observed is predominantly the non-scarring type. The mechanism matters more than the label does. Eli Lilly's own wording attributes it to hair loss associated with the weight reduction rather than caused by the drug, and a 2026 systematic review found rapid weight loss was a likely contributor, with women disproportionately affected. This is usually telogen effluvium, diffuse shedding triggered by a physiological stressor, and it typically appears 2 to 4 months after the trigger rather than during it. That delay is why most people blame the wrong thing. It also points at what to do, because rate of loss, protein intake and nutrient status are all adjustable. At T Clinics USA the provider managing your dosing and the provider evaluating your hair are the same practice and the same record. Results vary by individual.